News Headlines

  1. Modernizing mRNA Quality Control 5/20/2026

    Oxford Nanopore Technologies, a company delivering a new generation of nanopore-based molecular sensing technology, and Lonza today announced the launch of a new technology approach designed to modernize and accelerate GMP quality control testing for mRNA therapeutics.

  2. Bristol Myers Squibb Announces Strategic Agreement With Anthropic To Position Claude Enterprise As The Shared Intelligence Platform Across Its Global Operations 5/20/2026

    Bristol Myers Squibb, a global biopharmaceutical leader, today announced a strategic agreement with Anthropic to deploy Claude across the company's research, clinical development, manufacturing, commercial, and corporate functions.

  3. Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement For U.S. Commercialization Rights To IMPAVIDO® (Miltefosine) 5/19/2026

    Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has entered into a supply and distribution agreement for the United States commercialization rights to IMPAVIDO® (miltefosine) from an affiliate of Knight Therapeutics, Inc (“Knight”).

  4. Hansa Biopharma Enters Into €115M Licensing Agreement With SERB Pharmaceuticals For IDEFIRIX In Europe And MENA 5/19/2026

    Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ STOCKHOLM: HNSA) and SERB S.A. ("SERB") today announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.

  5. FAMAR Group Announces Contract Manufacturing Agreement With GE HealthCare 5/19/2026

    FAMAR Group, a leading European pharmaceutical Contract Development and Manufacturing Organization (CDMO), has signed a contract manufacturing agreement with GE HealthCare to fill and finish vials of GE HealthCare's iodine-based contrast media, at its newly acquired site in Homburg, Germany, with commercial supply due to begin in 2028.

  6. LOTTE Biologics Expands Antibody Manufacturing Agreement With Ottimo Pharma 5/18/2026

    LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic partnership.

  7. Parabilis Medicines Announces Strategic Collaboration With Regeneron Pharmaceuticals To Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas 5/18/2026

    Parabilis Medicines today announced a strategic research collaboration with Regeneron Pharmaceuticals, Inc. to discover and develop multiple therapeutic candidates based on Parabilis’s Helicon peptide platform, with a particular focus on Antibody-Helicon Conjugates (AHCs), a novel class of therapeutics designed to target challenging and historically “undruggable” targets.

  8. Piramal Pharma Solutions Announces Partnership With Botanix To Support Drug Substance Development 5/18/2026

    Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has entered a manufacturing and supply arrangement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT) ("Botanix"), a commercial dermatology company.

  9. LambdaVision And Helogen Partner To Advance Space-Based Biomaterial Manufacturing 5/18/2026

    LambdaVision, a pre-clinical-stage biotech advancing on-Earth and microgravity bioprocesses, today announced a strategic partnership with Helogen Corporation to launch a joint orbital manufacturing mission of LambdaVision’s artificial retina protein aboard Helogen’s fully autonomous manufacturing system in low-Earth orbit.

  10. ImmunityBio Signs Exclusive U.S. Agreement With Japan BCG Laboratory For The Tokyo Strain Of BCG To Enhance BCG Supply In The United States 5/16/2026

    ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory ("JBL"), the Tokyo-based developer and manufacturer of the Tokyo strain of BCG (Tokyo-172 BCG). The agreement provides ImmunityBio exclusive U.S. rights to develop, import, and commercialize intravesical Tokyo-172 BCG.